tooluniverse-gpcr-structural-pharmacology
This Claude Code skill integrates GPCR structural biology, pharmacological classification, and antibody engineering data to support drug discovery workflows. Use it to classify ligands by pharmacological mechanism (agonist, antagonist, biased agonist), retrieve and analyze GPCR crystal structures from GPCRdb, compare mutations using Ballesteros-Weinstein numbering across receptor subtypes, and identify therapeutic antibody structures via SAbDab for receptor-targeted therapeutics.
git clone --depth 1 https://github.com/mims-harvard/ToolUniverse /tmp/tooluniverse-gpcr-structural-pharmacology && cp -r /tmp/tooluniverse-gpcr-structural-pharmacology/plugin/skills/tooluniverse-gpcr-structural-pharmacology ~/.claude/skills/tooluniverse-gpcr-structural-pharmacologySKILL.md
# GPCR and Structural Pharmacology Research
**GPCR pharmacology**: agonist vs antagonist vs inverse agonist vs biased agonist — each has different clinical implications. Biased agonism (preferential G-protein vs β-arrestin signaling) can separate efficacy from side effects; for example, G-protein-biased opioid agonists aim to retain analgesia while reducing β-arrestin-mediated respiratory depression. Always classify retrieved ligands by their pharmacological type, not just their chemical structure. Receptor state (active vs inactive crystal structure) determines which ligands and mutations are interpretable — an inactive-state structure is appropriate for antagonist binding analysis, active-state for agonist-bound complexes. Generic GPCR numbering (Ballesteros-Weinstein) enables cross-receptor mutation comparison; always report positions in this system alongside sequence positions.
**LOOK UP DON'T GUESS**: never assume GPCRdb entry names (e.g., `adrb2_human`) or PDB IDs — always use `GPCRdb_list_proteins` to find the correct entry name and `GPCRdb_get_structures` to confirm available structures.
Research skill integrating GPCRdb (GPCR receptor biology), SAbDab (antibody structures), and PDBePISA (protein interface analysis) to support structural pharmacology, antibody engineering, and GPCR-targeted drug discovery.
**KEY PRINCIPLES**:
1. **Receptor-first** — Identify GPCR entry name before any GPCRdb queries
2. **Ligand classification** — Distinguish agonists, antagonists, partial agonists, biased agonists
3. **Structure-guided** — Pair GPCRdb mutation data with PDB structures via PDBePISA
4. **Antibody context** — Use SAbDab for therapeutic antibody structure retrieval and CDR analysis
5. **English-first queries** — Use standard receptor names (e.g., "beta-2 adrenergic receptor") in searches; convert to GPCRdb entry names for API calls
---
## When to Use
Apply when user asks:
- "What ligands are known for [GPCR receptor]?"
- "What crystal structures exist for [receptor]?"
- "Find antibody structures targeting [antigen]"
- "Analyze the protein-protein interface in PDB [ID]"
- "What mutations affect [GPCR] function or pharmacology?"
- "Which GPCRs are in the [family] family?"
- "What are the CDR loops in antibody PDB [ID]?"
- "What is the biological assembly for [PDB ID]?"
---
## Tool Parameter Reference (CRITICAL)
| Tool | Key Parameters | Notes |
|------|---------------|-------|
| `GPCRdb_get_protein` | `protein` | GPCRdb entry name (e.g., `adrb2_human`), NOT gene symbol or UniProt accession |
| `GPCRdb_list_proteins` | `family` (optional), `protein_class` (optional) | Lists all GPCRs; filter by family slug (e.g., `"adrenoceptors"`) OR by human-readable class name via `protein_class` (e.g., `"chemokine receptors"`, `"opioid receptors"`) |
| `GPCRdb_get_structures` | `protein` (optional), `state` (optional) | `state`: `"active"`, `"inactive"`, `"intermediate"` |
| `GPCRdb_get_ligands` | `protein` | Returns agonists, antagonists, biased ligands with affinities |
| `GPCRdb_get_mutations` | `protein` | Returns mutation effects on receptor function and ligand binding |
| `SAbDab_search_structures` | `query` | Antigen name, species, or keywords; returns browse URL + metadata |
| `SAbDab_get_structure` | `pdb_id` | 4-character PDB code (e.g., `"6W41"`); returns CDR annotations |
| `SAbDab_get_summary` | (no required params) | Database statistics and summary |
| `PDBePISA_get_interfaces` | `pdb_id` | 4-character PDB code; returns all interface pairs with buried area |
| `PDBePISA_get_assemblies` | `pdb_id` | Predicted biological assemblies from crystal packing |
| `PDBePISA_get_monomer_analysis` | `pdb_id` | Per-chain solvent-accessible surface area (SASA) breakdown |
### GPCRdb Entry Name Format
GPCRdb uses its own entry name format: `{receptor_slug}_{species}`. Common examples:
- Beta-2 adrenergic receptor: `adrb2_human`
- Beta-1 adrenergic receptor: `adrb1_human`
- Mu-opioid receptor: `oprm1_human`
- Dopamine D2 receptor: `drd2_human`
- Glucagon-like peptide-1 receptor: `glp1r_human`
- CXCR4 chemokine receptor: `cxcr4_human`
If entry name is unknown, use `GPCRdb_list_proteins()` to browse and find the correct slug. You can also filter by receptor class using the `protein_class` parameter with a human-readable name — e.g., `GPCRdb_list_proteins(protein_class="chemokine receptors")` — instead of the numeric family slug. Both `family` and `protein_class` are accepted and serve overlapping purposes; prefer `protein_class` when the user provides a receptor class name.
---
## Workflow Overview
```
Phase 1: Receptor Identification (for GPCR queries)
-> GPCRdb_list_proteins: find receptor family and entry name
-> GPCRdb_get_protein: receptor details, family, species
Phase 2: Ligand Landscape
-> GPCRdb_get_ligands: all known ligands by pharmacology class
-> Cross-reference with ChEMBL/PubChem for chemical properties
Phase 3: Structural Data
-> GPCRdb_get_structures: available PDB/EMDB structures with resolution
-> PDBePISA_get_interfaces: interface analysis on best structure
-> PDBePISA_get_assemblies: biological assembly determination
Phase 4: Mutation & Pharmacology Data
-> GPCRdb_get_mutations: pharmacological mutation map
-> Compare to ligand binding sites from structure
Phase 5: Antibody Structures (for antibody queries)
-> SAbDab_search_structures: find structures by antigen
-> SAbDab_get_structure: CDR annotations, chain details
-> PDBePISA_get_interfaces: antibody-antigen interface analysis
```
---
## Phase 1: GPCR Receptor Identification
```python
# List all GPCRs in a family to find entry name (by slug)
family_list = GPCRdb_list_proteins(family="adrenoceptors")
# Filter by human-readable class name (new -- preferred when user says e.g. "chemokine receptors")
chemokine_list = GPCRdb_list_proteins(protein_class="chemokine receptors")
# Browse all GPCRs (no family filter)
all_gpcrs = GPCRdb_list_proteins()
# Get detailed protein info once you hInstall and configure ToolUniverse for any use case — MCP server (chat-based), CLI (command line with 9 subcommands), or Python SDK (Coding API with 3 calling patterns). Covers uv/uvx setup, MCP configuration for 12+ AI clients (Cursor, Claude Desktop, Windsurf, VS Code, Codex, Gemini CLI, Trae, Cline, etc.), full CLI reference (tu list/grep/find/info/run/test/status/build/serve), Coding API quickstart, agentic tools, code executor, API key walkthrough, skill installation, and upgrading. Use when user asks how to set up ToolUniverse, which access mode to use (MCP vs CLI vs SDK), configuring MCP servers, using the CLI, troubleshooting installation, upgrading, or mentions installing ToolUniverse or setting up scientific tools. Also triggers for "how do I use ToolUniverse", "what's the best way to access tools", "command line", "tu command", "coding API", "tu build".
Systematic ACMG/AMP germline variant classification with all 28 criteria (PVS1, PS1-4, PM1-6, PP1-5, BA1, BS1-4, BP1-7) for clinical significance. Produces 5-tier verdict (Pathogenic / Likely Pathogenic / VUS / Likely Benign / Benign) with cited evidence per criterion. Use for variant interpretation, VUS resolution, and pathogenicity assessment. Combines ClinVar, gnomAD, computational predictors, and gene-mechanism context.
Comprehensive ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) profiling for drug candidates. Integrates ADMET-AI predictions, SwissADME drug-likeness, PubChemTox experimental toxicity, ChEMBL clinical data, Lipinski rule-of-five, and CYP interaction data. Use for drug-likeness assessment, BBB penetration, bioavailability, hepatotoxicity prediction, ADME/PK profiling, or screening compound libraries before lab testing.
Detect and analyze adverse drug event signals using FDA FAERS reports, drug labels, and disproportionality statistics (PRR, ROR, IC). Generates quantitative safety signal scores (0-100) with evidence grading. Use for post-market surveillance, pharmacovigilance, drug safety assessment, regulatory submissions, and detecting rare AE signals not visible in clinical trials.
Map environmental and industrial chemicals to adverse outcome pathways (AOPs) — molecular initiating event to organ-level toxicity. Uses AOPWiki, GHS classification, IARC carcinogen status, and LD50 data. Use for environmental/industrial chemical risk assessment, regulatory-grade hazard characterization, and AOP stressor mapping. Distinct from drug-safety analysis (use tooluniverse-pharmacovigilance for drugs).
Aging biology, cellular senescence, and longevity research. Covers senescence markers (p16/CDKN2A, SASP, SA-beta-gal), aging hallmarks, senolytic drug discovery (dasatinib+quercetin, fisetin, navitoclax), epigenetic clocks, telomere biology, and longevity GWAS. Use for senescence-pathway analysis, age-related disease genetics, senolytic-target discovery, and centenarian-genetics queries. Distinguishes correlative vs causal evidence (knockout, intervention).
Therapeutic antibody engineering and optimization, lead-to-clinical-candidate. Covers sequence humanization (germline alignment, framework retention), affinity maturation, developability (aggregation, stability, PTMs), structure modeling (AlphaFold/PDB CDR analysis), immunogenicity prediction, and manufacturing feasibility. Use for biologic-drug optimization, mAb design review, biosimilar engineering, and clinical-precedent comparison.
Discover novel small-molecule binders for protein targets using structure-based and ligand-based screening. Covers druggability assessment, known-ligand mining (ChEMBL, BindingDB), similarity expansion, ADMET filtering, and synthesis feasibility. Use for hit identification, virtual screening, target-to-compounds workflows, and lead-finding before commit-to-medchem.